MMP-2, MMP-9, and TIMP-4 and Response to Aspirin in Diabetic and Nondiabetic Patients with Stable Coronary Artery Disease: A Pilot Study

Figure 2

An influence of HPR on platelets release of MMP-2, MMP-9, and TIMP-4 without (a–c) or with (d–f) pretreatment with parenteral form of aspirin. Mean ± SEM classification of HPR on the basis of LTA Amax > 20%. HPR-high on-aspirin treatment platelets reactivity; LTA: light transmittance aggregometry; MMP: matrix metalloproteinase; TIMP-4: tissue inhibitor of MMPs.

(a)

(b)

(c)

(d)

(e)

(f)